Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 803 results for "alexion pharmaceuticals"

FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with...

Alexion Pharmaceuticals to Report Third Quarter 2016 Results o...

By a News Reporter-Staff News Editor at Pharma Business Week Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced that the Company will report its financial results for the third quarter ended September 30, 2016 on Thursday, October 27, 2016 ... Pharmacy Choice, 13 hours ago

70 images for alexion pharmaceuticals

American Banking News, 3 days ago
American Banking News, 3 days ago
Mideast Time, 4 days ago
WKRB News, 4 days ago
American Banking News, 3 weeks ago
Octafinance, 2 weeks ago
Zolmax News, 3 weeks ago
Business Insider Malaysia, 1 week ago
Share Market Updates, 1 week ago
Nasdaq, 3 weeks ago

Alexion Pharma Receives $194 Price Target

Alexion Pharmaceuticals' (NASDAQ: ALXN ) specialty is marketing and developing drugs that treat life-threatening conditions. Its flagship product, Soliris, is approved for treating two types of ultra-rare blood disorders: paroxysmal nocturnal ...
 Seeking Alpha3 weeks ago

Alexion Graft-Versus-Host Disease Drug Wins Orphan Status

Alexion Pharmaceuticals, Inc. ALXN announced that the FDA has granted orphan drug designation (ODD) to its pipeline candidate, ALXN1007, for the treatment of acute graft-versus-host disease (GVHD). The FDA, through its Office of Orphan Products ...
 Yahoo! Finance4 days ago Taking Aim at Alexion, Ra Pharma Heads to IPO Queue  Xconomy3 weeks ago Fabry's Disease Market Overview, Analysis & Forecast 2023  MyNewsDesk5 days ago Paroxysmal Nocturnal HemoglobinuriaPipeline Review H2 2016: Latest Study of Top Companies with Competitive Landscape  Before It's News5 days ago

Alexion (ALXN) Q3 Earnings: Can the Stock Pull a Surprise?

Alexion Pharmaceuticals, Inc. ALXN is scheduled to report third-quarter 2016 results on Oct 27, before the opening bell. The company's track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions.
 Zacks.com4 days ago

Biotech Stocks on Investors' Radar -- Alexion Pharma, PDL BioPharma, BioCryst Pharma, and Cara Therapeutics

NEW YORK , October 12, 2016 /PRNewswire/ -- US markets went back to a bearish environment following Monday's bullish performance. On Tuesday, the NASDAQ Composite ended the trading session down 1.54%; the Dow Jones Industrial Average lost 1.09%; ...
 Minyanville1 week ago Biotech Stocks on Investors'' Radar -- Alexion Pharma, PDL BioPharma, BioCryst Pharma, and Cara Therapeutics  Nasdaq1 week ago Biotech Stocks on Investors Radar — Alexion Pharma, PDL BioPharma, BioCryst Pharma, and...  Freshnews.com1 week ago CARA THERAPEUTICS : Biotech Stocks on Investors' Radar -- Alexion Pharma, PDL BioPharma, BioCryst Pharma, and Cara Therapeutics  4 Traders1 week ago

New drug costs $2mln for a one-year course

A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for limited use by Britain's health cost watchdog. The ...
 News.am1 month ago A pair of biotech IPOs line up: Myovant and Ra Pharma  FierceBiotech3 weeks ago UK okays Alexion drug costing up to $2 mln but wants price cut  Sharenet1 month ago UPDATE 1-UK okays Alexion drug costing up to $2 mln but wants price cut  Business Insider1 month ago

Integrated Wealth Management Maintains Stake in Alexion Pharmaceuticals Inc. (ALXN)

Integrated Wealth Management maintained its position in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) during the second quarter, Holdings Channel reports. The institutional investor owned 1,100 shares of the biopharmaceutical company's stock ...
 Ticker Report2 days ago Alexion Pharmaceuticals Inc. (ALXN) Stock Rating Lowered by Vetr Inc.  Ticker Report15 hours ago Carsten Thiel Sells 4,584 Shares of Alexion Pharmaceuticals Inc. (ALXN) Stock  WKRB News4 days ago Public Employees Retirement Association of Colorado Sells 1,652 Shares of Alexion Pharmaceuticals Inc. (ALXN)  Zolmax News4 days ago

Alexion Pharmaceuticals (ALXN) Trading Near $115.61 Support Level

( via COMTEX) -- A covered call identified by's patented algorithm on Alexion Pharmaceuticals could yield about 3.54% (41.66% annualized, for comparison purposes only) in 31 days. Pair a long ...
 TradingCharts.com6 days ago Alexion Pharmaceuticals (ALXN) Showing Bullish Technicals With Resistance At $127.45  TradingCharts.com2 weeks ago


By Targeted News Service ALEXANDRIA, Va., Oct. 20 -- Alexion Pharmaceuticals, New Haven, Connecticut, has been assigned a patent (9,469,690) developed by four co-inventors for the "methods of treating complement-associated disorders with anti-C5a ...
 4 Traders4 days ago Alexion Pharmaceuticals Assigned Patent  Pharmacy Choice4 days ago

Potential Alexion Pharmaceuticals (ALXN) Trade Has 5.09% Downside Protection

( via COMTEX) --'s option-trade picking algorithms have identified an attractive covered-call trade on Alexion Pharmaceuticals . Look at the Nov 18, 2016 $120 covered call for a net debit in ...
 TradingCharts.com5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - alexion pharmaceuticals
Get updated on latest news & your favorite topics right in your inbox!
More     Less